Leerink Partnrs Brokers Decrease Earnings Estimates for BMY

Bristol-Myers Squibb (NYSE:BMY) – Analysts at Leerink Partnrs reduced their FY2026 EPS estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings of $6.32 per share for the year, down from their previous estimate of $6.33. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Bristol-Myers Squibb’s current full-year earnings is $0.92 per share. Leerink Partnrs also issued estimates for Bristol-Myers Squibb’s FY2027 earnings at $6.72 EPS and FY2028 earnings at $6.60 EPS.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The business had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. During the same quarter in the previous year, the business earned $2.00 EPS. The company’s quarterly revenue was up 8.4% compared to the same quarter last year.

BMY has been the topic of a number of other research reports. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $50.00 price objective on shares of Bristol-Myers Squibb in a research note on Friday, October 18th. TD Cowen boosted their price objective on Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. BMO Capital Markets increased their price target on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a research note on Tuesday. Sanford C. Bernstein initiated coverage on Bristol-Myers Squibb in a research note on Thursday, October 17th. They issued a “market perform” rating and a $56.00 price target on the stock. Finally, Jefferies Financial Group increased their price objective on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a research report on Wednesday, August 28th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, two have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $54.07.

Bristol-Myers Squibb Stock Performance

NYSE:BMY traded up $0.70 during midday trading on Thursday, hitting $59.11. The company’s stock had a trading volume of 494,000 shares, compared to its average volume of 14,382,672. The firm has a market cap of $119.89 billion, a P/E ratio of -16.28, a P/E/G ratio of 21.34 and a beta of 0.44. The firm’s 50 day moving average is $52.41 and its 200-day moving average is $47.07. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $61.08. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were paid a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.06%. Bristol-Myers Squibb’s dividend payout ratio is presently -66.85%.

Insider Activity

In related news, EVP Samit Hirawat purchased 1,830 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The shares were purchased at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the transaction, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. The trade was a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 1,830 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was acquired at an average cost of $54.67 per share, with a total value of $100,046.10. Following the purchase, the executive vice president now owns 62,109 shares in the company, valued at approximately $3,395,499.03. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Phil M. Holzer sold 700 shares of the stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the transaction, the senior vice president now owns 11,760 shares of the company’s stock, valued at $654,091.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

Institutional Trading of Bristol-Myers Squibb

A number of institutional investors have recently bought and sold shares of BMY. Atomi Financial Group Inc. purchased a new stake in shares of Bristol-Myers Squibb in the first quarter valued at about $231,000. TD Asset Management Inc increased its position in Bristol-Myers Squibb by 2.7% during the first quarter. TD Asset Management Inc now owns 1,648,245 shares of the biopharmaceutical company’s stock worth $89,384,000 after buying an additional 42,682 shares in the last quarter. HBK Sorce Advisory LLC raised its holdings in shares of Bristol-Myers Squibb by 3.7% in the first quarter. HBK Sorce Advisory LLC now owns 32,578 shares of the biopharmaceutical company’s stock worth $1,767,000 after acquiring an additional 1,159 shares during the last quarter. Wintrust Investments LLC lifted its position in shares of Bristol-Myers Squibb by 9.7% in the first quarter. Wintrust Investments LLC now owns 39,652 shares of the biopharmaceutical company’s stock valued at $2,150,000 after acquiring an additional 3,515 shares in the last quarter. Finally, TCTC Holdings LLC increased its position in Bristol-Myers Squibb by 0.9% during the 1st quarter. TCTC Holdings LLC now owns 443,544 shares of the biopharmaceutical company’s stock worth $24,053,000 after purchasing an additional 3,909 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.